



**COMPANY ANNOUNCEMENT
(ASX: ANP)**

Results of Annual General Meeting

Thursday, 12th of November 2015

The Company wishes to advise that all resolutions considered from the Notice of Meeting were carried on a show of hands.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at its Annual General Meeting held on Thursday, 12th of November 2015.

	Resolution	For	Against	Abstain	Undirected*	For Percentage**
1	Non-binding resolution to adopt the 2015 Remuneration Report ***	42,989,673	7,205,880	5,179,259	36,019	85.65%
2	Approve the previous issue of 15,025,075 Shares to Cortendo AB	33,169,449	7,166,863	15,038,500	36,019	82.25%
3	Approval of 10% Placement Facility***	48,161,161	7,200,226	13,425	36,019	87.00%

* The Chairman voted undirected proxy's in his control in favour of all resolutions.

** For Percentage includes undirected votes at the control of the Chairman voted in favour.

*** Resolution 1 and 3 are special resolutions and require 75% approval to be passed. This threshold has been achieved and the resolutions passed.

For and on behalf of the Board;

A handwritten signature in black ink, appearing to read "Robert Moses", written over a white background.

Mr Robert Moses
Chairman



CHAIRMAN'S ADDRESS TO 2015 AGM

Ladies and Gentleman, I am pleased to report to you that, since we met last year your Company has further progressed its antisense product portfolio and significantly enhanced the fundamental value of your company in terms of both its secure current financial condition and importantly the prospect of substantial future cash flows. In addition to the upfront cash payment received from licensing our ATL1103 acromegaly product to Nasdaq-listed Strongbridge Biopharma, potential future cash flows from this deal include milestone payments totaling up to A\$ 177 million* and potential for up to double digit royalties. We have also added significantly to our patent portfolio and substantially strengthened the Board. The Company also continues to have the support of our partner, Isis Pharmaceuticals who most of you will recognise is the clear world leader in antisense technology and a major player in the rapidly growing RNA therapeutics sector. Antisense Therapeutics operates in the same RNA therapeutics sector.

In bringing two new U.S. based Directors onto the Board, Bill Goolsbee and Gary Pace, we are adding exceptionally strong experience and expertise in the global pharmaceutical industry. This will be particularly beneficial to ANP with respect to our strategic positioning, partnering and investor interactions in the U.S. Both Bill and Gary have extensive U.S. capital market and industry connections.

Our Company now has a solid platform to build on, proven science, and two mature Phase II drugs, one of which is already licensed with the potential to earn substantial future revenue. Accordingly we are optimistic and confident that the Company's best days are ahead of us. We have a very good story to tell, and we are telling it; not only here in Australia, but overseas – in particular the USA – and our story is being told to both the investment community and the pharmaceutical and biotech industries. I refer you to the first few pages of our Annual Report for a more comprehensive review of the past years activities and accomplishments.

I would like to personally thank our Management Team. They have worked tirelessly and tenaciously to build value in the Company for all shareholders which as you most likely know includes Isis and Strongbridge as well as the Board and Management.

Finally, on behalf of both Board and Management, I would like to express our appreciation for our many loyal, long term shareholders who continue to be supportive. Your support is reflected in the proxy voting and demonstrates that you continue to have confidence that Antisense Therapeutics will deliver the value you expect and deserve.

A handwritten signature in black ink, appearing to read "Robert W. Moses".

Chairman

- Subject to A\$/USD currency fluctuation